Payment overview · 2025
General Payments
$4,768.80
204 reported records · 20 companies
Healthcare provider profile · identity verified
Rajiv Kumar, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · AGOURA HILLS, CA · NPI 1689681173
Verified facts
What the public records show
CMS Open Payments records show Rajiv Kumar, M.D. received $4,768.80 in general payments during 2025 across 204 reported records.
ABBVIE INC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adzenys Xr-Odt.
Neos Therapeutics, LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adzenys XR-ODT as an associated drug or biological on 3241 records involving 1599 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Adzenys Xr-Odt by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,598.32 | 33.5% | 61 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $524.80 | 11.0% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $312.21 | 6.5% | 12 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $255.12 | 5.3% | 19 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $242.79 | 5.1% | 12 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $241.55 | 5.1% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $225.12 | 4.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.45 | 4.3% | 24 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $188.09 | 3.9% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $166.88 | 3.5% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $146.05 | 3.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $115.91 | 2.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $115.89 | 2.4% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $109.84 | 2.3% | 5 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $97.31 | 2.0% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $63.82 | 1.3% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.63 | 1.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.69 | 1.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.24 | 0.9% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $20.09 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,768.80 | 204 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $916.82 | 34 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $749.92 | 27 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $619.87 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $609.11 | 24 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $312.21 | 12 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $255.12 | 19 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $241.55 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $204.45 | 24 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $204.45 | 24 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $188.09 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $166.88 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $146.05 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $123.46 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $115.91 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $115.89 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $109.84 | 5 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $79.89 | 4 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $78.55 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $63.82 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $47.69 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| Quillichew ER Normalized: quillichew er |
Drug | Tris Pharma Inc | $39.44 | 3 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| EXXUA Normalized: exxua |
Drug | Neos Therapeutics, LP | $18.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adzenys XR-ODT adzenys xr odt |
2025 | Adzenys Xr-Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neos Therapeutics, LP Exact reporting entity; no affiliate inference |
2025 | Adzenys XR-ODT open payments reported associated product |
CMS Open Payments — General Payments 3241 supporting records · 1599 recipient NPIs · example record 1206088044 |
Adzenys Xr-Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 33 |
| Bupropion Xl | Bupropion Hcl | 158 | 34 |
| Alprazolam | Alprazolam | 155 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 26 |
| Gabapentin | Gabapentin | 117 | 24 |
| Trazodone Hcl | Trazodone Hcl | 103 | 18 |
| Clonazepam | Clonazepam | 97 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 79 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 73 | suppressed |
| Lorazepam | Lorazepam | 70 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 63 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Clozapine | Clozapine | 53 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 40 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Adzenys Xr-Odt | Amphetamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,768.80 · 204 records | ABBVIE INC. | ALVESCO, ARISTADA, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, EXXUA, FANAPT, HORIZANT, Jornay PM, LOREEV XR, LYBALVI, NURTEC ODT, Onyda XR, QULIPTA, Qelbree, Quillichew ER, REXULTI, TRINTELLIX, UBRELVY, VRAYLAR, WAKIX, Xelstrym, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adzenys Xr-Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neos Therapeutics, LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error